Despite recent progress in targeted molecular therapies (anti‐FLT3, anti‐IDH1, IDH2 or anti‐Bcl2), AML treatment has remained essentially the same for 30 years and is still based on variants of the classic “backbone 3 + 7”, associating anthracycline and cytarabine, especially in young and/or fit AML patients. This evidence concerns the gene IDH1 and acute myeloid leukemia.